For instance, mutations in DDR2, NTRK, MAP2K1, AKT1, NRAS, and PIK3CA have clinical importance in a small proportion of patients with non-small cell lung cancer (NSCLC) (Faehling et al., 2017[17]; Pao and Girard, 2011[54]), thus such potential mutations need to be reviewed properly whether to be included or not. This evidence concerns the gene NRAS and non-small cell lung carcinoma.